LUNG CANCER

Investigators of the GEMSTONE-302 trial announced finding a statistically significant benefit in overall survival with sugemalimab in patients with non–small cell lung cancer.

The FDA is reviewing a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy as a first-line treatment option for patients with advanced non-small cell lung cancer.

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed how to approach treating patients with lung cancer with rare mutations that can be targeted by certain treatments.

Interim results from the phase 3 KEYNOTE-091 show promise for the use of pembrolizumab in patients with stage IB-IIIA non–small cell lung cancer treated in the adjuvant setting.

During a Targeted Oncology Case-Based Roundtable event, Chul Kim, MD, MPH, assistant professor at Georgetown University, discussed immunotherapy options for patients with non–small cell lung cancer with PD-L1 expression.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Fifty percent of patients in the first 2 cohorts of an early-phase study experienced stable disease on annamycin, and no dose-limiting toxicities were observed.

A phase 3 trial of consibelimab aims to enroll 560 patients with non–small cell lung cancer, who will be randomized to receive either consibelimab with chemotherapy, or chemotherapy alone.

Lurbinectedin is being evaluated as treatment of patients with small cell lung cancer in a phase 3 trial.

The most effective treatment strategy—adjuvant, neoadjuvant, or some combination of adjuvant plus neoadjuvant regimens— remains unclear. Ongoing trials are dedicated to defining the best sequence of treatment.

Two oncologists give their expert take on KRAS- and EGFR-mutant non–small cell lung cancer.

During a live virtual event, Ravi Salgia, MD, PhD, discussed how to decide whether to use a MET inhibitor in the first line and whether to switch to a MET inhibitor from other treatments.

Based on the case of a 59-year-old Asian man with non-small cell lung cancer, Jason Niu, MD discusses the targeted therapy options for the disease.

A 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.

Joel Neal, MD, PhD and Karen Kelly, MD recently teamed up to moderate a roundtable discussion around molecular testing and choice of treatment for a 59-year-old patient with non–small cell lung cancer.

Julie R. Brahmer, MD, MSc, FASCO, cochair of the upcoming 19th Annual Winter Lung Cancer Conference, has seen the full development of immunotherapy era in lung cancer from the beginning.

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

Karen Reckamp, MD, and Jyoti Patel, MD, discuss unmet needs, novel treatment strategies, and future perspectives for patients with ALK+ advanced NSCLC.

Jyoti Patel, MD, and Karen Reckamp, MD, evaluate the treatment of patients with ALK+ advanced NSCLC with brain metastases.

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

Karen Reckamp, MD, and Jyoti Patel, MD, outline their treatment approaches for patients with ALK+ NSCLC who progress on frontline TKIs.

Jyoti Patel, MD, and Karen Reckamp, MD, share insights on factors to consider when selecting the appropriate therapy for patients with ALK+ advanced NSCLC.

Nino Balanchivadze, MD, FACP, discusses the methods used in the retrospective analysis of KEYNOTE-189 study, to determine the differences in the rate of renal toxicity based on race in patients with non-squamous non-small cell lung cancer.